6:03 AM ET
8-K
Business Update
ArriVent BioPharma Business Update
ArriVent BioPharma announced the dosing of the first patient in its U.S. Phase 1 clinical trial of ARR-002, a potential first-in-class dual-target antibody-drug conjugate (ADC). The trial is evaluating the safety and efficacy of the candidate in patients with advanced or metastatic ovarian and endometrial cancer.